Synopsis
Synopsis
0
VMF
0
Australia
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Calan
2. Cordilox
3. Dexverapamil
4. Falicard
5. Finoptin
6. Hydrochloride, Verapamil
7. Iproveratril
8. Isoptin
9. Isoptine
10. Izoptin
11. Lekoptin
12. Verapamil
1. 152-11-4
2. Verapamil Hcl
3. Manidon
4. Cordilox
5. Calcan Hydrochloride
6. Verelan
7. (+/-)-verapamil Hydrochloride
8. Cardibeltin
9. Isoptin
10. Calan
11. 23313-68-0
12. Verapamil (hydrochloride)
13. Cardiabeltin
14. Cardioprotect
15. Veroptinstada
16. Berkatens
17. Calaptin
18. Cardiagutt
19. Caveril
20. Civicor
21. Coraver
22. Corpamil
23. Dignover
24. Durasoptin
25. Geangin
26. Harteze
27. Hexasoptin
28. Hormitol
29. Ikapress
30. Inselon
31. Isoptino
32. Izoptin
33. Jenapamil
34. Lodixal
35. Magotiron
36. Praecicor
37. Robatelan
38. Vasomil
39. Vasopten
40. Verabeta
41. Veracor
42. Verahexal
43. Veraloc
44. Veramex
45. Veramil
46. Verapin
47. Verasal
48. Verasifar
49. Veratensin
50. Verdilac
51. Vetrimil
52. Akilen
53. Elthon
54. Flamon
55. Ikacor
56. Quasar
57. Univer
58. Univex
59. Vortac
60. Anpec
61. Ormil
62. Rapam
63. Verapamil Ebewe
64. Verapamil Riker
65. Verapamil Verla
66. Civicor Retard
67. Isoptin Retard
68. Manidon Retard
69. Vera-sanorania
70. Verapamil Acis
71. Verapamil Atid
72. Novo-veramil
73. Verapamil Basics
74. Verapamil Nordic
75. Verapamil-abz
76. Novapamyl Lp
77. Verapamil Al
78. Verapamil Nm
79. Verapamil Pb
80. Verapamil Sr
81. Verapamyl Hydrochloride
82. Apo-verap
83. Cordilox Sr
84. Dilacoran Hta
85. Veracaps Sr
86. Verapamil Msd
87. Arpamyl Lp
88. Hexasoptin Retard
89. Isoptin Sr
90. Nu-verap
91. Verapamil Henning
92. Verelan Sr
93. Covera-hs
94. Covera
95. Calan Sr
96. Verapamil Injection
97. Verapamil Nm Pharma
98. Calaptin 240 Sr
99. Verapress 240 Sr
100. Mfcd00055208
101. 5-((3,4-dimethoxyphenethyl)(methyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile Hydrochloride
102. Nsc-272366
103. Nsc-657799
104. Mls000069485
105. V3888oey5r
106. Nsc657799
107. Lu-20175
108. Smr000059109
109. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Hydrochloride
110. 5-[n-(3,4-dimethoxyphenylethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile Hydrochloride
111. ( Inverted Exclamation Marka)-verapamil Hydrochlorid
112. Verapamil Chloridrate
113. D-365 Hydrochloride
114. Iproveratril Hydrochloride
115. 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile;hydrochloride
116. 5-[(3,4-dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxy Phenyl)-2-isopropylvaleronitrile Hydrochloride
117. Nsc272366
118. Sr-01000000050
119. Einecs 205-800-5
120. Nsc 272366
121. Unii-v3888oey5r
122. Lu 20175
123. C27h38n2o4.hcl
124. Verapamil, Hcl
125. Verapamil-d7 Hcl
126. Prestwick_440
127. Vasolan (tn)
128. Verelan (tn)
129. Covera-hs (tn)
130. Calan (tn)
131. Isotopin Hydrochloride
132. Verapamil Hydrochloride [usan:usp:jan]
133. Verapamili Hydrochloridum
134. Opera_id_1210
135. ()-verapamil Hydrochlorid
136. Cas-152-11-4
137. (y)-verapamil Hydrochloride
138. (?)-verapamil Hydrochloride
139. Chembl1280
140. Dsstox_cid_14095
141. Dsstox_rid_79114
142. Verapamil Hydrochloride,(s)
143. Dsstox_gsid_34095
144. Schembl33296
145. 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile Monohydrochloride
146. Benzeneacetonitrile, Alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, Monohydrochloride
147. Mls001055442
148. Mls002222213
149. (+-)-verapamil Hydrochloride
150. Spectrum2300307
151. Dtxsid2034095
152. Hms1568m04
153. Hms1922j16
154. Pharmakon1600-02300307
155. Bcp06465
156. Hy-a0064
157. Tox21_201180
158. Tox21_501237
159. Verapamil Hydrochloride [mi]
160. Ccg-39491
161. Nsc759589
162. S4202
163. Verapamil Hydrochloride (jp17/usp)
164. Verapamil Hydrochloride [jan]
165. Verapamil Hydrochloride [hsdb]
166. Verapamil Hydrochloride [usan]
167. Akos005267117
168. Ac-8483
169. Cs-1685
170. Lp01237
171. Nsc-759589
172. Verapamil Hydrochloride [mart.]
173. Verapamil Hydrochloride [vandf]
174. Verapamil Hydrochloride [usp-rs]
175. Verapamil Hydrochloride [who-dd]
176. Verapamil Hydrochloride [who-ip]
177. Ncgc00024710-03
178. Ncgc00094479-01
179. Ncgc00094479-02
180. Ncgc00094479-03
181. Ncgc00094479-04
182. Ncgc00094479-05
183. Ncgc00258732-01
184. Ncgc00261922-01
185. (+-)-5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile Monohydrochloride
186. 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile Hydrochloride
187. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl]methylamino}-2-(methy Lethyl)pentanenitrile, Chloride
188. Ac-16228
189. As-16018
190. Benzeneacetonitrile, Alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, Monohydrochloride, (+-)-
191. Bv164516
192. Sy073165
193. Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl-, Monohydrochloride
194. Eu-0101237
195. Ft-0603360
196. Ft-0630593
197. Ft-0655647
198. Ft-0675800
199. Sw196662-4
200. V0118
201. Verapamil Hydrochloride [ep Impurity]
202. Verapamil Hydrochloride [orange Book]
203. Tarka Component Verapamil Hydrochloride
204. Verapamil Hydrochloride [ep Monograph]
205. D00619
206. D78147
207. D88195
208. V 4629
209. Verapamil Hydrochloride [usp Monograph]
210. ( Inverted Question Mark)-verapamil Hydrochloride
211. Verapamil Hydrochloride Component Of Tarka
212. Verapamili Hydrochloridum [who-ip Latin]
213. 152v114
214. A816666
215. Q-201923
216. Sr-01000000050-2
217. Sr-01000000050-4
218. (+/-)-verapamil, Hydrochloride - Cas 152-11-4
219. Q27291481
220. Sr-01000000050-11
221. Z2210978706
222. (+/-)-verapamil Hydrochloride, >=99% (titration), Powder
223. Verapamil Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
224. Verapamil Hydrochloride, European Pharmacopoeia (ep) Reference Standard
225. Verapamil Hydrochloride, United States Pharmacopeia (usp) Reference Standard
226. (+/-)-5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile Monohydrochloride
227. (+/-)-verapamil Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
228. 2-(3,4-dimethoxyphenyl)-5-[[2-(3,4-dimethoxyphenyl)-ethyl](methyl)amino]-2-isopropylpentanenitrile Hydrochloride
229. 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-propan-2-yl-pentanenitrile Hydrochloride
230. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-isopropylpentanenitrile Hydrochloride
231. 5-((3,4-dimethoxyphenethyl)(methyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrilehydrochloride
232. 5-[(3,4-dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile Hydrochloride
233. Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl) Benzeneacetonitrile Hydrochloride
234. Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile Hydrochloride (1:1)
235. Benzeneacetonitrile, .alpha.-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-.alpha.-(1-methylethyl)-, Monohydrochloride, (+/-)-
236. Benzeneacetonitrile,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-.alpha.-(1-methylethyl)-, Monohydrochloride
237. Verapamil Hydrochloride Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
Molecular Weight | 491.1 g/mol |
---|---|
Molecular Formula | C27H39ClN2O4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 13 |
Exact Mass | 490.2598354 g/mol |
Monoisotopic Mass | 490.2598354 g/mol |
Topological Polar Surface Area | 64 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 606 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Verapamil hydrochloride |
Drug Label | Verelan (verapamil hydrochloride capsules) is a calcium ion influx inhibitor (slow channel blocker or calcium ion antagonist). Verelan is available for oral administration as a 360 mg hard gelatin capsule (lavender cap/yellow body), a 240 mg hard g... |
Active Ingredient | Verapamil hydrochloride |
Dosage Form | Tablet, extended release; Tablet; Injectable; Capsule, extended release |
Route | Injection; Oral |
Strength | 180mg; 200mg; 2.5mg/ml; 120mg; 300mg; 100mg; 80mg; 40mg; 240mg |
Market Status | Prescription |
Company | Hospira; Apotex; Sun Pharm Inds; Par Pharm; Watson Labs; Glenmark Generics; Ivax Sub Teva Pharms; Mylan; Heritage Pharms |
2 of 2 | |
---|---|
Drug Name | Verapamil hydrochloride |
Drug Label | Verelan (verapamil hydrochloride capsules) is a calcium ion influx inhibitor (slow channel blocker or calcium ion antagonist). Verelan is available for oral administration as a 360 mg hard gelatin capsule (lavender cap/yellow body), a 240 mg hard g... |
Active Ingredient | Verapamil hydrochloride |
Dosage Form | Tablet, extended release; Tablet; Injectable; Capsule, extended release |
Route | Injection; Oral |
Strength | 180mg; 200mg; 2.5mg/ml; 120mg; 300mg; 100mg; 80mg; 40mg; 240mg |
Market Status | Prescription |
Company | Hospira; Apotex; Sun Pharm Inds; Par Pharm; Watson Labs; Glenmark Generics; Ivax Sub Teva Pharms; Mylan; Heritage Pharms |
Calcium Channel Blockers
A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
70
PharmaCompass offers a list of Verapamil Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Verapamil Hydrochloride manufacturer or Verapamil Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Verapamil Hydrochloride manufacturer or Verapamil Hydrochloride supplier.
PharmaCompass also assists you with knowing the Verapamil Hydrochloride API Price utilized in the formulation of products. Verapamil Hydrochloride API Price is not always fixed or binding as the Verapamil Hydrochloride Price is obtained through a variety of data sources. The Verapamil Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Manidon Retard manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Manidon Retard, including repackagers and relabelers. The FDA regulates Manidon Retard manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Manidon Retard API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Manidon Retard manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Manidon Retard supplier is an individual or a company that provides Manidon Retard active pharmaceutical ingredient (API) or Manidon Retard finished formulations upon request. The Manidon Retard suppliers may include Manidon Retard API manufacturers, exporters, distributors and traders.
click here to find a list of Manidon Retard suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Manidon Retard DMF (Drug Master File) is a document detailing the whole manufacturing process of Manidon Retard active pharmaceutical ingredient (API) in detail. Different forms of Manidon Retard DMFs exist exist since differing nations have different regulations, such as Manidon Retard USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Manidon Retard DMF submitted to regulatory agencies in the US is known as a USDMF. Manidon Retard USDMF includes data on Manidon Retard's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Manidon Retard USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Manidon Retard suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Manidon Retard Drug Master File in Japan (Manidon Retard JDMF) empowers Manidon Retard API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Manidon Retard JDMF during the approval evaluation for pharmaceutical products. At the time of Manidon Retard JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Manidon Retard suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Manidon Retard Drug Master File in Korea (Manidon Retard KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Manidon Retard. The MFDS reviews the Manidon Retard KDMF as part of the drug registration process and uses the information provided in the Manidon Retard KDMF to evaluate the safety and efficacy of the drug.
After submitting a Manidon Retard KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Manidon Retard API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Manidon Retard suppliers with KDMF on PharmaCompass.
A Manidon Retard CEP of the European Pharmacopoeia monograph is often referred to as a Manidon Retard Certificate of Suitability (COS). The purpose of a Manidon Retard CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Manidon Retard EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Manidon Retard to their clients by showing that a Manidon Retard CEP has been issued for it. The manufacturer submits a Manidon Retard CEP (COS) as part of the market authorization procedure, and it takes on the role of a Manidon Retard CEP holder for the record. Additionally, the data presented in the Manidon Retard CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Manidon Retard DMF.
A Manidon Retard CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Manidon Retard CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Manidon Retard suppliers with CEP (COS) on PharmaCompass.
A Manidon Retard written confirmation (Manidon Retard WC) is an official document issued by a regulatory agency to a Manidon Retard manufacturer, verifying that the manufacturing facility of a Manidon Retard active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Manidon Retard APIs or Manidon Retard finished pharmaceutical products to another nation, regulatory agencies frequently require a Manidon Retard WC (written confirmation) as part of the regulatory process.
click here to find a list of Manidon Retard suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Manidon Retard as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Manidon Retard API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Manidon Retard as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Manidon Retard and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Manidon Retard NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Manidon Retard suppliers with NDC on PharmaCompass.
Manidon Retard Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Manidon Retard GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Manidon Retard GMP manufacturer or Manidon Retard GMP API supplier for your needs.
A Manidon Retard CoA (Certificate of Analysis) is a formal document that attests to Manidon Retard's compliance with Manidon Retard specifications and serves as a tool for batch-level quality control.
Manidon Retard CoA mostly includes findings from lab analyses of a specific batch. For each Manidon Retard CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Manidon Retard may be tested according to a variety of international standards, such as European Pharmacopoeia (Manidon Retard EP), Manidon Retard JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Manidon Retard USP).